View More Recent Stories

Jan 22, 2025 02:48PM CRISPR Therapeutics (CRSP) sees mid-day trading action
Jan 13, 2025 07:01AM CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and Anticipated 2025 Milestones
Jan 7, 2025 08:04AM CRISPR Therapeutics (CRSP) Proposes New Appointment to the Board of Directors
Jan 4, 2025 04:00PM 2025 Biopharma sector outlook
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 18, 2024 05:08PM Clear Street Starts CRISPR Therapeutics (CRSP) at Hold
Dec 9, 2024 12:01PM CRISPR Therapeutics (CRSP) Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Nov 6, 2024 09:25AM TD Cowen Reiterates Sell Rating on CRISPR Therapeutics (CRSP)
Nov 6, 2024 06:15AM Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
Nov 5, 2024 03:25PM CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners
Aug 6, 2024 09:26AM TD Cowen Reiterates Sell Rating on CRISPR Therapeutics (CRSP)
Aug 6, 2024 07:17AM CRISPR Therapeutics (CRSP) PT Lowered to $84 at Needham
Aug 6, 2024 07:11AM CRISPR Therapeutics (CRSP) PT Lowered to $59 at Stifel
Aug 6, 2024 06:43AM CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
Aug 5, 2024 04:04PM CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c
Jul 23, 2024 09:05AM TD Cowen Reiterates Sell Rating on CRISPR Therapeutics (CRSP)
Jun 17, 2024 07:49AM Piper Sandler Reiterates Overweight Rating on CRISPR Therapeutics (CRSP)
View More Recent Stories